Endovascular thrombectomy for acute ischemic stroke ameta-analysis

JAMA - Journal of the American Medical Association

Volumn 314, Issue 17, 2015, Pages 1832-1843

  Badhiwala, Jetan H ^a   Nassiri, Farshad ^a   Alhazzani, Waleed ^b   Selim, Magdy H ^c   Farrokhyar, Forough ^b   Spears, Julian ^a   Kulkarni, Abhaya V ^a   Singh, Sheila ^b   Alqahtani, Abdulrahman ^d   Rochwerg, Bram ^b   Alshahrani, Mohammad ^e   Murty, Naresh K ^b   Alhazzani, Adel ^f   Yarascavitch, Blake ^g   Reddy, Kesava ^b   Zaidat, Osama O ^h   Almenawer, Saleh A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

^e IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^f KING KHALID UNIVERSITY   (Saudi Arabia)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

ALL CAUSE MORTALITY; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAUSE OF DEATH; FOLLOW UP; HUMAN; META ANALYSIS; MORTALITY; MULTICENTER STUDY (TOPIC); PERCUTANEOUS THROMBECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; RISK ASSESSMENT; SURGICAL RISK; SYSTEMATIC REVIEW; THROMBECTOMY DEVICE; TREATMENT OUTCOME; AGED; ENDOVASCULAR SURGERY; FEMALE; MALE; MIDDLE AGED; PROCEDURES; STROKE; THROMBECTOMY;

AGED; ENDOVASCULAR PROCEDURES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBECTOMY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84946057438     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.13767     Document Type: Article

References (48)

1. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-Analysis. Lancet. 2012;379 (9834): 2364-2372.
2. Emberson J, Lees KR, Lyden P, et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolys is with alteplase for acute ischaemic stroke: ameta-Analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929-1935.
3. Lees KR, Bluhmki E, von Kummer R, et al; ECAS S, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695-1703.
4. Jauch EC, Saver JL, Adams HP Jr, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870-947.
5. de Los Ríos la Rosa F, Khoury J , Kissela BM, et al. Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial. Stroke. 2012;43(6):1591-1595.
6. RiboM, Alvarez-Sabín J, Montaner J, et al. Temporal profile of recanalization after intravenous tissue plasminogen activator: selecting patients for rescue reperfusion techniques. Stroke. 2006;37(4): 1000-1004.
7. Saqqur M, Uchino K, Demchuk AM, et al; CLOTBUST Investigators. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke. 2007;38(3):948-954.
8. Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009;40 (8):2761-2768.
9. SmithWS, Sung G, Saver J, et al; Multi MERCI Investigators. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke. 2008;39(4):1205-1212.
10. Meyers PM, Schumacher HC, Connolly ES Jr, Heyer EJ, GrayWA, Higashida RT. Current status of endovascular stroke treatment. Circulation. 2011; 123(22):2591-2601.
11. Osanai T, Pasupuleti V, Deshpande A, et al. Acute endovascular reperfusion therapy in ischemic stroke: a systematic review and meta-Analysis of randomized controlled trials. PLoS One. 2015;10(4): e0122806.
12. Singh B, Parsaik AK, Prokop LJ,Mittal MK. Endovascular therapy for acute ischemic stroke: a systematic review and meta-Analysis. Mayo Clin Proc. 2013;88(10):1056-1065.
13. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. BMJ. 2009;339:b2535.
14. Higgins JPT, G reen S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [March 2011]. The Cochrane Collaboration; 2011.
15. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.
16. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-607.
17. Higgins JP, Altman DG, G øtzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statis tical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
18. Brott T,Adams HP Jr,Olinger CP,et al Measurements of acute cerebral infarction: a clinical examination scale Stroke 1989 20 7 864-870.
19. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet. 2000;355(9216):1670-1674.
20. Campbell BC, Donnan GA, Lees KR, et al. Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke. Lancet Neurol. 2015;14(8):846-854.
21. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency inmeta-Analyses. BMJ. 2003;327(7414):557-560.
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-Analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
24. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-1101.
25. Copas JB, Shi JQ. A sensitivity analysis for publication bias in systematic reviews. Stat Methods Med Res. 2001;10(4):251-265.
26. Ciccone A, Valvassori L, Nichelatti M, et al; SYNTHESIS Expansion Investigators. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013;368(10):904-913.
27. Kidwell CS, Jahan R, Gornbein J, et al; MR RESCUE Investigators. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368(10):914-923.
28. Broderick JP, Palesch YY, Demchuk AM, et al; Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368(1 0):893-903.
29. Berkhemer OA, Fransen PS, Beumer D, et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11-20 .
30. Goyal M, Demchuk AM, Menon BK, et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019-1030.
31. Campbell BC, Mitchell PJ, Kleinig TJ, et al; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11):1009-1018.
32. Saver JL, Goyal M, Bonafe A, et al; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372(24):2285-2295.
33. J ovin TG, Chamorro A, Cobo E, et al; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296-2306.
34. Intracerebral hem orrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. 1997;28(11):2109-2118.
35. Kwiatkowski TG, Libman RB, Frankel M, et al; National Institute of Ne urological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med. 1999;340(23):1781-1787.
36. Adams HP Jr, Adams RJ, Brott T, et al; Stroke Council of the American Stroke Association. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the Amer ican Stroke Association. Stroke. 2003;34(4):1056-1083.
37. ArnoldM, Schroth G, Gralla J. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013;368(25):2431.
38. Cohen JE, Leker RR. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013;368 (25):2432.
39. Bhatia R, Shobha N, Menon BK, et al. Combined full-dose IV and endovascular thrombolysis in acute ischaemic stroke. Int J Stroke. 2014;9(8):974-979.
40. Mazighi M,Meseguer E,Labreuche J,Amarenco P Bridging therapy in acute ischemic stroke: a systematic review and meta-Analysis Stroke 2012 43 5 1302-1308
41. Mazighi M, Serfaty JM, Labreuche J, et al; RECANALISE investigators. Comparison of intravenous alteplase with a c ombined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol. 2009;8(9):802-809.
42. Yoo DS,Won YD, Huh PW, et al. Therapeutic results of intra-Arterial thrombolysis after full-dose intravenous tissue plasminogen activator administration. AJNR Am J Neuroradiol. 2010;31(8): 1536-1540.
43. Katz JM, Gobi n YP. Merci Retriever in acute stroke treatment. Expert Rev Med Devices. 2006;3 (3):273-280.
44. Saver JL, Jahan R, Levy EI, et al; SWIFT Trialists. Solitaire flow restoration device v ersus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet. 2012;380(9849):1241-1249.
45. Nogueira RG, Lutsep HL, Gupta R, et al; TREVO 2 Trialists. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet. 2012;380(9849):1231-1240.
46. Furlan A, Higashida R,Wechsler L, et al; Prolyse in Acute Cerebral Thromboembolism. Intra-Arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. JAMA. 1999;282(21):2003-2011.
47. Wechsler LR, Roberts R, Furlan AJ, et al; PROACT II Investigators. Factors influencing outcome and treatment effect in PROACT II. Stroke. 2003;34(5):1224-1229.
48. Zivin JA. Factors determining the therapeutic window for stroke. Neurology. 1998;50(3):599-603.